J&J drug for rare cancer performs well in Phase II study

|By:, SA News Editor

Johnson & Johnson's (JNJ) Siltuximab drug reduced tumors in a Phase II trial of 79 patients with Castleman disease, a very rare condition that is characterized by enlarged lymph nodes and for which there are no approved therapies.

A third of the subjects who received siltuximab responded vs none who were given a placebo. A quarter had all symptoms of the disease completely resolved for a median period of 1.3 years.